Hay T - Search Results

1

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.

Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ. Ordonez LD, et al. Among authors: hay t. Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5. Oncotarget. 2019. PMID: 31080552 Free PMC article.

2

Mutations in Apc and p53 synergize to promote mammary neoplasia.

Méniel V, Hay T, Douglas-Jones A, Sansom OJ, Clarke AR. Méniel V, et al. Among authors: hay t. Cancer Res. 2005 Jan 15;65(2):410-6. Cancer Res. 2005. PMID: 15695381

3

Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells.

Hay T, Patrick T, Winton D, Sansom OJ, Clarke AR. Hay T, et al. Oncogene. 2005 May 26;24(23):3842-6. doi: 10.1038/sj.onc.1208533. Oncogene. 2005. PMID: 15735671

4

DNA damage hypersensitivity in cells lacking BRCA2: a review of in vitro and in vivo data.

Hay T, Clarke AR. Hay T, et al. Biochem Soc Trans. 2005 Aug;33(Pt 4):715-7. doi: 10.1042/BST0330715. Biochem Soc Trans. 2005. PMID: 16042582 Review.

5

Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.

Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR. Hay T, et al. Cancer Res. 2005 Nov 15;65(22):10145-8. doi: 10.1158/0008-5472.CAN-05-1186. Cancer Res. 2005. PMID: 16287996

6

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR. Hay T, et al. Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383921

7

RNA Interference Using c-Myc-Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models.

Tangudu NK, Verma VK, Clemons TD, Beevi SS, Hay T, Mahidhara G, Raja M, Nair RA, Alexander LE, Patel AB, Jose J, Smith NM, Zdyrko B, Bourdoncle A, Luzinov I, Iyer KS, Clarke AR, Dinesh Kumar L. Tangudu NK, et al. Among authors: hay t. Mol Cancer Ther. 2015 May;14(5):1259-69. doi: 10.1158/1535-7163.MCT-14-0970. Epub 2015 Feb 18. Mol Cancer Ther. 2015. PMID: 25695957 Free article.

8

APC2 is critical for ovarian WNT signalling control, fertility and tumour suppression.

Mohamed NE, Hay T, Reed KR, Smalley MJ, Clarke AR. Mohamed NE, et al. Among authors: hay t. BMC Cancer. 2019 Jul 10;19(1):677. doi: 10.1186/s12885-019-5867-y. BMC Cancer. 2019. PMID: 31291912 Free PMC article.

9

Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model.

Tornillo G, Warrington L, Kendrick H, Higgins AT, Hay T, Beck S, Smalley MJ. Tornillo G, et al. Among authors: hay t. Dis Model Mech. 2024 Jan 1;17(1):dmm050211. doi: 10.1242/dmm.050211. Epub 2024 Jan 25. Dis Model Mech. 2024. PMID: 38149669 Free PMC article.

10

Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency.

Gallagher RC, Hay T, Meniel V, Naughton C, Anderson TJ, Shibata H, Ito M, Clevers H, Noda T, Sansom OJ, Mason JO, Clarke AR. Gallagher RC, et al. Among authors: hay t. Oncogene. 2002 Sep 19;21(42):6446-57. doi: 10.1038/sj.onc.1205892. Oncogene. 2002. PMID: 12226748

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters